Affiliation:
1. University of Diponegoro, Semarang, Indonesia
2. Dr. Kariadi Centra l Hospital, Semarang, Indonesia
Abstract
Aim – This study aimed to analyze the association between B-Raf proto-oncogene, serine/threonine kinase (BRAF) V600E and tumor size, lymph node, and distant metastasis (TNM) status on patients with papillary thyroid carcinoma. Material and Methods – This research is a cross-sectional study. A total of 40 samples were papillary thyroid carcinoma tissue paraffin blocks from thyroidectomy surgery at State General Hospital (RSUP) Dr. Kariadi Semarang. Assessment of BRAF V600E mutation protein expression through immunohistochemical methods using antibody BRAF V600E was conducted. Results – The mean age of patients with papillary thyroid carcinoma with a positive BRAF V600E mutation was 49 years. The highest incidence was 71.4% in women. A significant difference between BRAF V600E and tumor size (p=0.03) was observed with as many as 53.2% more cases at size > 4 cm. A significant difference in the expression of BRAF V600E with enlargement of the lymph node (p=0.011) by 60.7% was observed compared to those without enlarged lymph nodes. On the other hand, no significant relationship between BRAF V600E expression and distant metastasis (p=0.652) was observed. The prevalence ratio in the positive BRAF V600E case at tumor size is more than 4 cm, and enlargement of lymph is 9.533 and 7.727. Conclusion – There is a significant relationship between BRAF V600E expression and tumor size and enlarged lymph nodes, while there is no significant relationship between BRAF V600E expression and distant metastases.
Publisher
LLC Science and Innovations
Reference25 articles.
1. Abd Elmageed ZY, Sholl AB, Tsumagari K, Al-Qurayshi Z, Basolo F, Moroz K, et al. Immunohistochemistry as an accurate tool for evaluating BRAF-V600E mutation in 130 samples of papillary thyroid cancer. Surgery 2017; 161(4): 1122-1128. https://doi.org/10.1016/j.surg.2016.06.081.
2. Ellys, Kartika I, Aspitriani, Yuwono. Galectin-3 expression level as a marker of benign and malignant lesions of the thyroid. Jurnal Kedokteran dan Kesehatan 2015; 2(3): 311-317. Indonesian. https://media.neliti.com/media/publications/181704-ID-tingkat-ekspresi-galectin-3-sebagai-pena.pdf.
3. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistic. CA Cancer J Clin 2011; 61(2): 69-90. https://doi.org/10.3322/caac.20107.
4. Rosai J, Delellis RA, Carcangiu ML, Frable WJ, Tallini G. AFIP Atlas Of Tumor Pathology: Tumors of the Thyroid and Parathyroid Glands. Silver Spring, Maryland: American Registry of Pathology. 2014; 606 p. https://www.worldcat.org/title/tumors-of-the-thyroid-and-parathyroid-glands/oclc/904183558.
5. Enewold L, Zhu K, Ron E, Marrogi AJ, Stojadinovic A, Peoples GE, et al. Rising thyroid cancer incidence in the United States by demographic and tumor characteristics, 1980-2005. Cancer Epidemiol Biomarkers Prev 2009; 18(3): 784-791. https://doi.org/10.1158/1055-9965.epi-08-0960.